Unknown

Dataset Information

A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment.


ABSTRACT: Current treatments for inflammatory bowel disease (IBD) treatment consist of anti-inflammatory products. In this study, we sought to induce the physiological secretion of glucagon-like peptide 2, a peptide with intestinal growth-promoting activity, via nanoparticles while simultaneously providing with immunomodulation by tailoring the nanoparticle surface. To this end, we developed hybrid lipid hyaluronate-KPV conjugated nanoparticles loaded with teduglutide for combination therapy in IBD. The nanocarriers induced (or did not induce) immunosuppression depending on the presence (or absence) of a hyaluronan-KPV functionalization. This strategy holds promise as a nanoparticle platform for combined mucosal healing and immunomodulation in IBD treatment.

SUBMITTER: Marotti V 

PROVIDER: S-EPMC10582360 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature